Live Panel Discussion on Brexit's Impact on Clinical Trials - Separating Fact from Fiction
Using our knowledge of pharmaceutical development, clinical manufacturing and packaging solutions, PCI provides unparalleled expertise and a seamlessly integrated drug development service delivering speed-to-market and commercial success for our client's products.Click here for high-resolution version
PCI Pharma Services is an integrated full service provider, a proven and trusted partner to leading companies in the global healthcare industry.Click here for high-resolution version
/EINPresswire.com/ -- TORONTO, ON--(Marketwired - October 06, 2017) - In an upcoming webinar hosted by Xtalks, chaired by PCI Clinical Services' UK Managing Director Dr. Fiona Withey, a live panel will examine the facts around Brexit and its impact on clinical trials.
Current levels of uncertainty within post-Brexit clinical trial supply chains is leading to client, sponsor and patient concerns. To address these fears, the speakers will also outline their risk mitigation strategy to ensure continuity of their clients' supply chains and to allow patients to continue to access safe and effective medicines.
It is very hard for anybody not intimately involved with the European Union, the workings of the UK economy and the healthcare sector, to clearly understand the true facts, or indeed the advantages and disadvantages, of Brexit. One fact is clear, Brexit is happening in March 2019 and the UK will leave the European Union.
So what does Brexit mean for the pharmaceutical sector? As various bodies initiate debate and argument, leading to uncertainty, assumptions and surmising, it is becoming increasingly difficult to separate fact from fiction and understand the likely implications that Brexit will have on this sector.
With European Commission directives and cross-border collaborations currently in place, it is perceived that clinical supply chains will experience future challenges in terms of compliance with new rules and regulations that will be enforced post March 2019.
With the degree of 'Brexit uncertainty' appearing to be increasing, what is fact and what is fiction and what will be the impact on the pharmaceutical sector?
Join the live session on Monday, October 23, 2017 at 10am EDT (3pm BST/UK). For more information about this this complimentary event, visit: Brexit's Impact on Clinical Trials - Separating Fact from Fiction.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical and biotech companies, private and academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx
Image Available: http://www.marketwire.com/library/MwGo/2017/10/6/11G146302/Images/PCI_clinicalservices_logo_300-c2afc9f6fd42bb70bc6cf6e9f1948a72.jpg
Image Available: http://www.marketwire.com/library/MwGo/2017/10/6/11G146302/Images/PCI_Logo_200-6155c081b3e5988e8e42e7cd27cbf3de.jpg
Contact:
Nima Rajan
Tel: +1 (416) 977-6555 ext 352
Email: nrajan@xtalks.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
